Cardiovascular structure and function in the mucopolysaccharidoses - cardiovascular disease (CVD) is the leading cause of death in the world despite public health emphases upon treatment of…

Active Grant Awarded Last action

Award ID
R01HL173371
Recipient
Awarding agency
Obligated
$1,643,132

Award facts

Assistance listing
93.837 Cardiovascular Diseases Research
Completion date 28% complete
Place of performance
Orange, CA 92868, USA

Award details come from USAspending.gov.

Description

Cardiovascular structure and function in the mucopolysaccharidoses - cardiovascular disease (CVD) is the leading cause of death in the world despite public health emphases upon treatment of hyperlipidemia, hypertension, and diabetes mellitus. Cardiovascular manifestations are also a leading cause of mortality in two inherited conditions, mucopolysaccharidosis (MPS) types I and IVA. These rare diseases invite further investigation because affected individuals accumulate large quantities of glycosaminoglycans (GAGS). While GAGS are normal proteoglycan components of healthy cardiac valves, arterial parenchyma, and endothelial glycocalyx, excess quantities contribute to CVD pathogenesis but via poorly understood pathomechanisms. We present three interrelated, yet parallel aims: a clinical, a hybrid clinical/preclinical, and a preclinical trial which leverage our combined clinical and translational research expertise. This project examines human and murine MPS I and IVA to robustly probe the relationships between derangements in cardiovascular GAG content and cardiovascular structure and function. Aim 1 of this project prospectively assesses cardiac and arterial structure and function in a large cohort of MPS I and IVA patients, rigorously comparing with an equally large cohort of healthy matched controls to establish a MPS CVD natural history. Results from this aim will provide a clinical basis for evaluation of therapies targeting MPS cardiovascular symptoms. Aim 2 of this proposal will define and validate prognostic biomarkers of both human and murine MPS CVD. Results of these studies will greatly expand the understanding of proteoglycan function in cardiovascular health and disease. Aim 3 of this proposal will utilize the foundations previously established to evaluate efficacy of click-xyloside modulators of GAG biosynthesis and an inhibitor of elastin proteolysis to mitigate murine MPS cardiovascular manifestations. The result of these studies will determine preclinical efficacy of therapeutic compounds and inform future human therapeutic trials. The long-term goal of this study is to understand roles of cardiovascular GAGS and proteoglycans, validate biomarkers, and develop treatments to stop progression in MPS cardiovascular pathology.

Transactions

Action Obligated Date
Amendment $790,852
Original award $852,280

Subawards

Subrecipient Amount Awarded
Saint Louis University The purpose of this multi-site collaboration is to assess cardiac and carotid structure and function using carotid ultrasounds and echocardiograms. The… $241,255
Regents Of The University Of Minnesota University of Minnesota (UMN) will: • Recruit 29 MPS I and IVA subjects, who will have four annual carotid ultrasounds, echocardiograms, and blood draws •… $206,536
University Of Utah DELIVERABLES: Year 1: Deliverable 1: Synthesize, purify, confirm structure for first click-glycoside compound (VT250) 1) Provide 300 mg (first cohort of 10… $146,692

Quick answers

Who received award R01HL173371?

R01HL173371 was awarded to Children's Hospital Of Orange County by National Heart Lung and Blood Institute (National Institutes of Health) on July 15, 2025.

How much is award R01HL173371 worth?

$1,643,132 has been obligated on R01HL173371.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award